";s:4:"text";s:5247:" Homozygous deficiency in either TPMT or NUDT15 Because of the risk of increased toxicity, consider alternative therapies for patients who are known to have TPMT or NUDT15 deficiency Heterozygous deficiency in TPMT and/or NUDT15 Because of the risk of increased toxicity, dosage reduction is recommended in patients known to have heterozygous deficiency of TPMT or NUDT15. Hepatotoxicity following transplantation most often occurs within 6 months of transplantation and is generally reversible after interruption of azathioprine. sunspot_baby New Member Take your next dose at the regular time. 67877-492-38, Adult dosage (ages 18–64 years): The typical dosage is 600 mg twice per day. As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.Use with Angiotensin-Converting Enzyme Inhibitors: Store at 20°C to 25°C (68° to 77°F), (see USP Controlled Room Temperature) in a dry place and protect from light. Chronic immunosuppression with azathioprine, a purine antimetabolite increases Patients receiving immunosuppressants, including azathioprine, are at increased risk of developing lymphoma and other malignancies, particularly of the skin.
Usual Adult Dose for Hyperlipidemia: 600 mg orally twice a day, 30 minutes before the morning and evening meal.
67877-495-38 Halving azathioprine 50mg tablets (see advice on additional counselling required for halving tablets) Prescribing 50mg azathioprine tablets and changing the patient’s dosage regimen to alternate days (e.g.
Each film-coated tablet contains 25 mg azathioprine. In patients with severe myelosuppression, consider evaluation for TPMT and NUDT15 deficiency (see PRECAUTIONS: Laboratory Tests). Azathioprine can be discontinued abruptly, but delayed effects are possible.
The possibility that exacerbation of symptoms might be drug-related should be borne in mind when treating such patients.Pancreatitis has been reported in a small percentage of patients on azathioprine therapy, particularly in renal transplant patients and those diagnosed as having inflammatory bowel disease.
Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine. The blood count frequency may be reduced later in therapy, but it is recommended that complete blood counts are repeated monthly or at least at intervals of not longer than three months.Patients receiving azathioprine should be instructed to report immediately any evidence of infections, unexpected bruising or bleeding or other manifestations of bone marrow depression.Rare individuals with an inherited thiopurine methyltransferase (TPMT) deficiency may be unusually sensitive to azathioprine-induced myelosuppression and can be susceptible to rapid bone marrow depression following initiation of azathioprine therapy. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. In the rat model of adjuvant arthritis, azathioprine has been shown to inhibit the lymph node hyperplasia, which precedes the onset of the signs of the disease. If the patient is exposed to VZV, special care must be taken to avoid patients developing chickenpox or herpes zoster, and passive immunisation with varicella-zoster immunoglobulin (VZIG) may be considered.If the patient is infected with VZV, appropriate measures should be taken, which may include antiviral therapy and supportive care.Special care is necessary when azathioprine is given concomitantly with neuromuscular blocking agents such as atracurium, rocuronium, cisatracurium or suxamethonium (also known as succinylcholine) (see section 4.5). Due to inconsistencies between the drug labels on DailyMed and the pill images provided by 67877-493-01, color yellow shape round imprint 54 043 This medicine is a yellow, round, scored, tablet imprinted with "54 043". Azathioprine should not be given to patients who have shown hypersensitivity to the drug. Another inactivation pathway is oxidation, which is catalyzed by xanthine oxidase (XO) to form 6-thiouric acid. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. TPMT activity correlates inversely with 6-TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities.Genetic polymorphisms influence TPMT and NUDT15 activity.